Clinical trials: Diabetes Mellitus Type II,
Diabetes, Diabetes Mellitus, Type 2
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy and safety of liraglutide compared to sitagliptin, both as add-on to metformin in Chinese subjects with type 2 diabetes inadequately controlled…
- Trial name
- NCT02008682
- Testing
- liraglutide, sitagliptin
- Where
- 25 sites in China
- Volunteers
- 368 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes for 16 weeks administration.
- Trial name
- NCT02220920
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 146 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Diabetes Mellitus, Type 2
A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program
A pilot study titled "A Virtual Cardiometabolic Health Program for African Immigrants (The Afro-DPP Program) will be conducted to address the cardiometabolic of community-dwelling African immigrants who have multiple…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, PreDiabetes, Hypertension
- Trial name
- NCT05144737
- Testing
- The Diabetes Prevention Program
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Type 2 Diabetes Mellitus
Efficacy and Safety of Insulin Glargine/Lixisenatide Fixed Combination Versus Insulin Glargine Alone on Top of Metformin in Type 2 Diabetic Patients
Primary Objective: The purpose of this study was to compare insulin glargine/ lixisenatide fixed ratio combination (FRC) versus insulin glargine on glycemic control over 24 weeks, as evaluated by glycosylated hemoglobin (HbA1c)…
- Trial name
- NCT01476475
- Testing
- Insulin glargine /lixisenatide Fixed Ratio Combination, Insulin glargine, Metformin (Background drug)
- Where
- 70 sites in United States, Chile and 11 more
- Volunteers
- 323 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
The purpose of this study is to investigate the effect of bexagliflozin compared to sitagliptin as an add-on therapy to metformin in lowering hemoglobin A1c (HbA1c) levels in subjects with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT03115112
- Testing
- Bexagliflozin, Sitagliptin
- Where
- 56 sites in United States, Czechia and 4 more
- Volunteers
- 386 people
- Sponsor
- Theracos
Type 2 Diabetes Mellitus
An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.
- Trial name
- NCT00511472
- Testing
- MK-0941, LANTUS insulin
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Overweight, Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase.
- Trial name
- SURMOUNT-1 (NCT04184622)
- Testing
- Tirzepatide
- Where
- 118 sites in United States, Argentina and 8 more
- Volunteers
- 2,539 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
A Multiple Dose Investigational Drug Study in Patients With Type 2 Diabetes (MK-0941-005)
A multiple dose study to assess the safety and pharmacokinetics of an investigational drug in patients with type 2 diabetes. The primary hypotheses of the study are that multiple daily MK-0941 in subjects with T2DM with or…
- Trial name
- NCT00511667
- Testing
- MK0941
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)
This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to 17 year old diabetic patients.
- Trial name
- NCT00730275
- Testing
- Sitagliptin phosphate
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Type I Diabetes
A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes
The goal of the proposed pilot study is to determine whether glucose control can be improved with Bydureon treatment in patients with type I diabetes (T1D)
- Trial name
- NCT01928329
- Testing
- Exenatide (Bydureon®)
- Where
- 8 sites in United States
- Volunteers
- 79 people
- Sponsor
- Yale University
Hypertension
An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes
This study will examine the ability of olmesartan medoxomil to lower the blood pressure of patients with Type II diabetes and high blood pressure.
- Trial name
- NCT00403481
- Testing
- olmesartan medoxomil, Olmesartan medoxomil plus Hydrochlorothiazide
- Where
- 27 sites in United States
- Volunteers
- 192 people
- Sponsor
- Daiichi Sankyo
Diabetes Mellitus, Type 2
Liquid Meal Study With Insulin Lispro With/Without Recombinant Human Hyaluronidase PH20 (rHuPH20) and Regular Human Insulin With rHuPH20 to Compare Pharmacokinetics, Postprandial Glycemic Response, and Optimal Insulin Dose in Participants With Type 2 Diabetes Mellitus (T2DM)
This is a single-center, Phase 2, randomized, double-blind, 3-way crossover meal study in participants with Type 2 Diabetes Mellitus (T2DM) to determine the optimum dose and compare the pharmacokinetics (PK) and postprandial…
- Trial name
- NCT00916357
- Testing
- Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Halozyme Therapeutics
Type 2 Diabetes Mellitus
Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes
This Phase 3, open-label, multicenter study is designed to compare the effects of exenatide and insulin glargine (Lantus® injection) on beta-cell function in patients with type 2 diabetes mellitus using metformin.
- Trial name
- NCT00097500
- Testing
- exenatide, Insulin glargine, Metformin
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 69 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
The Effect of Januvia (Sitagliptin) on Oxidative Stress in Obese Type 2 Diabetic Subjects
Sitagliptin is a new oral hypoglycemic anti-diabetic drug used either alone or in combination with metformin or a thiazolidinedione for control of type 2 diabetes mellitus.
- Trial name
- 1928 (NCT00659711)
- Testing
- Januvia (Sitagliptin) 100 mg
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University at Buffalo
Type 2 Diabetes Mellitus
Randomized, Double-blind, Active-controlled, Study of Rivoglitazone in Type 2 Diabetes Mellitus
This is a 26-week, multicenter, randomized, double-blind, placebo and active comparator-controlled, parallel-group study in participants with type 2 diabetes currently sub-optimally controlled by diet and exercise or with…
- Trial name
- NCT00571519
- Testing
- Rivoglitazone HCl, pioglitazone HCl, pioglitazone HCl 45 mg
- Where
- 18 sites in United States
- Volunteers
- 94 people
- Sponsor
- Daiichi Sankyo
Chronic Kidney Diseases, Type 2 Diabetes
Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management
The goal of this study is to test whether a dipeptidyl peptidase-4 inhibitor, compared with a sulfonylurea, improves time in normal blood glucose range and reduces blood glucose variability.
- Trial name
- CANDY-CANE (NCT02608177)
- Testing
- Linagliptin, Glipizide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Washington
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 10773 at two different doses compared to placebo during long term treatment (78 weeks) in combination with basal insulin in patients…
- Trial name
- NCT01011868
- Testing
- BI 10773 low dose, BI 10773 high dose
- Where
- 99 sites in United States, Denmark and 5 more
- Volunteers
- 494 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
- Trial name
- NCT01664624
- Testing
- Roflumilast, Alogliptin, Exenatide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
Diabetes Mellitus Type 2
ENhancing Outcomes Through Goal Assessment and Generating Engagement in Diabetes Mellitus
The purpose of this study is to evaluate whether a combination of pharmacist-delivered patient engagement techniques improves disease control and medication adherence among patients with poorly-controlled diabetes compared with…
- Trial name
- ENGAGE-DM (NCT02910089)
- Testing
- Shared Decision Making
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"
The purpose of this survey is to evaluate the long-term safety and efficacy of trelagliptin tablets in patients with type 2 diabetes mellitus in the routine clinical setting.
- Trial name
- NCT03555591
- Testing
- Trelagliptin
- Where
- Japan
- Volunteers
- 3,198 people
- Sponsor
- Takeda